PROGNOSTIC ROLE OF MONOMERIC C-REACTIVE PROTEIN IN NEWLY DIAGNOSED MULTIPLE MYELOMA AS A MARKER OF THE BONE LOSS DEGREE

EHA Library, Sergey Semochkin, 324312

VALIDATION OF ALGORITHMS TO IDENTIFY FIRST-LINE THERAPY (INDUCTION AND MAINTENANCE) FOR MULTIPLE MYELOMA FOR USE IN ELECTRONIC HEALTHCARE DATABASES

EHA Library, Ariel Berger, 324313

COMPARISON OF THE EXPRESSION PROFILE AND PROMOTER GENE METHYLATION OF SELECTED TUMOR-SUPPRESSOR GENES IN MYELOMA CELLS

EHA Library, Katerina Smesny Trtkova, 324314

EFFICACY AND SAFETY OF VENETOCLAX COMBINATIONS IN T(11;14) MULTIPLE MYELOMA: REAL WORLD DATA OF 50 PATIENTS COLLECTED FROM 7 HUNGARIAN CENTERS

EHA Library, Virág Szita, 324315

FIRST CASE OF SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS TREATED WITH ANTI-B CELL MATURATION ANTIGEN -CAR T CELLS

EHA Library, Aina Oliver Caldés, 324316

OUTCOMES OF DARATUMUMAB-CONTAINING REGIMENS IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA: REAL-WORLD DATA FROM THE CANADIAN MYELOMA RESEARCH GROUP DATABASE

EHA Library, Richard LeBlanc, 324317

THE NATURAL HISTORY OF SYSTEMIC AL AMYLOIDOSIS FOLLOWING UPFRONT TREATMENT WITH BORTEZOMIB: AN ANALYSIS OF REAL-WORLD LONGITUDINAL DATA

EHA Library, Sriram Ravichandran, 324318

A CLINICAL-DECISION TOOL TO IMPROVE THE STRATEGY OF MULTIPLE MYELOMA TREATMENT

EHA Library, Alexander Luchinin, 324319

IN-CLASS TRANSITION FROM INTRAVENOUS TO ORAL PROTEASOME INHIBITOR AS LONG PROTEASOME INHIBITION IN NEWLY DIAGNOSED AND FIRST RELAPSED MULTIPLE MYELOMA PATIENTS IN CHINA: A REAL-WORLD STUDY

EHA Library, Aijun Liu, 324320

EFFICACY AND SAFETY OF INDUCTION THERAPY WITH IAD VERSUS IRD REGIMEN IN FRAGILE ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA-RESULTS OF PROSPECTIVE MULTICENTER CLINICAL TRAIL

EHA Library, Li Bao, 324321

RISK ASSESSMENT MODEL FOR IMMUNOMODULATORY DRUG-ASSOCIATED VENOUS THROMBOSIS AMONG PATIENTS WITH MULTIPLE MYELOMA IN CHINA

EHA Library, Juan Li, 324322

REAL-LIFE DATA ON THE SAFETY AND EFFICACY OF CARFILZOMIB AND LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN 149 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS OF GEMMAC GROUP.

EHA Library, Antonio Garcia-Guiñon, 324323

HIGH LEVELS OF GALECTIN-3 AND IMMUNOGLOBULIN LIGHT CHAINS AS MARKERS OF THE RISK OF PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE IN RESIDENTS OF GOMEL REGION OF BELARUS

EHA Library, Zhanna Kozich, 324324

ANALYSIS OF DELAY IN THE DIAGNOSIS OF MULTIPLE MYELOMA IN A SANITARY REGION OF SOUTHERN SPAIN.

EHA Library, Leire Sanz Rekalde, 324325

REAL-WORLD EVIDENCE OF CARFILZOMIB USE AMONG MULTIPLE MYELOMA PATIENTS WITH AT LEAST ONE PRIOR THERAPY ACROSS 4 COUNTRIES IN CENTRAL EASTERN EUROPE AND ISRAEL

EHA Library, Yael Cohen, 324326

MODIFIED DELPHI CONSENSUS ON THE RELEVANCE OF MINIMAL RESIDUAL TESTING IN MULTIPLE MYELOMA IN THE CLINICAL PRACTICE

EHA Library, Karthik Ramasamy, 324327

A RETROSPECTIVE TWO-CENTRE COHORT STUDY OF THE EFFICACY AND SAFETY OF DARATUMUMAB WITH BORTEZOMIB AND DEXAMETHASONE THERAPY FOR PREVIOUSLY TREATED MULTIPLE MYELOMA

EHA Library, IRENE SANCHEZ PRIETO, 324328

LIGHTHOUSE (OP-108): A PHASE 3 STUDY OF MELFLUFEN IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB VS DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 324329

WHOLE BODY MRI IS A FEASIBLE AND COST-EFFECTIVE IMAGING MODALITY FOR WORK-UP OF SUSPECTED OR NEWLY DIAGNOSED MULTIPLE MEYLOMA: A RETROSPECTIVE, SINGLE CENTRE COHORT STUDY

EHA Library, Richard Buka, 324330

AL AMYLOIDOSIS SURVIVAL EVOLUTION IN NEW AGENTS ERA : A REAL LIFE EXPERIENCE

EHA Library, Ornella Rizzo, 324331

RECOMMENDATIONS FOR VACCINATION GIVEN TO PATIENTS WITH MULTIPLE MYELOMA IN REAL-WORLD CLINICAL PRACTICE AND PATIENTS` COMPLIANCE WITH THEM

EHA Library, Heinz Ludwig, 324332

COVID-19 MORTALITY IN CONCURRENT MULTIPLE MYELOMA (MM) – A PROSPECTIVE AND COMPARATIVE CASE SERIES THROUGH THE FIRST AND SECOND WAVE OF THE SARS-COV-2 PANDEMIC IN A UK TERTIARY HAEMATOLOGY CENTRE

EHA Library, Sammy Shaya, 324333

CARFILZOMIB USE AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE ASIA PACIFIC REGION: AN INTERIM ANALYSIS FROM A PROSPECTIVE, REAL-WORLD STUDY

EHA Library, Hang Quach, 324334

BCMA-DIRECTED THERAPY IN MULTIPLE MYELOMA: EFFECT OF ONLINE EDUCATION ON CLINICIAN KNOWLEDGE AND CONFIDENCE

EHA Library, Amanda Taylor, 324335

A DESCRIPTIVE COST-ANALYSIS OF MYX.1/MCRN003 - A PHASE 2 CLINICAL TRIAL EVALUATING HIGH-DOSE WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Bethany Monteith, 324336

RACIAL DISPARITIES OF OUTCOME IN MULTIPLE MYELOMA COMPARATIVE ANALYSIS OF VARIED ETHNIC GROUPS IN GALILEE, ISRAEL

EHA Library, Najib Dally, 324337

TREATMENT FOR NEWLY DIAGNOSED, FIT AND YOUNG PATIENTS WITH MULTIPLE MYELOMA: 'ONE SIZE FITS ALL’’ OR PERSONALIZED TREATMENT APPROACHES SHOULD BE CONSIDERED?

EHA Library, Fatema Abbas, 324338

MULTIPLE MYELOMA TREATMENT DECISIONS FROM THE PATIENT PERSPECTIVE

EHA Library, Matthew Lyall, 324339

BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD) AS FIRST LINE THERAPY IN MULTIPLE MYELOMA PATIENTS. REAL LIFE EXPERIENCE IN A SINGLE INSTITUTION.

EHA Library, Dunia De Miguel Llorente, 324340

THE IMPACT OF COVID-19 ON PATIENT DISEASE EXPERIENCE: INSIGHTS FROM SOCIAL MEDIA POSTS CONTRIBUTED BY PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Rebecca Crawford, 324341

THE PATIENT EXPERIENCE OF MULTIPLE MYELOMA: SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE

EHA Library, Courtney Levy, 324342

PHASE 2 MARCH STUDY OF ORAL ATG-010 PLUS LOW DOSE DEXAMETHASONE IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY EXPOSED TO AN IMMUNOMODULATORY AGENT AND A PROTEASOME INHIBITOR

EHA Library, Weijun Fu, 324343

VALIDATION OF THE MYRADS REPORTING CRITERIA USING DATA FROM A PROSPECTIVE IMAGING STUDY IN PLASMA CELL DYSCRASIAS (LOOMIS).

EHA Library, Guido Nador, 324344

REDEFINING OUTCOMES IN MULTIPLE MYELOMA IN COVID-19 INFECTED PATIENTS. RECONSIDERING THE THROMBOSIS AND INFECTIVE RISK.

EHA Library, Harberth Fernandez - Leyva, 324345

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA IN DIFFERENT GEOGRAPHICAL REGIONS: FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW

EHA Library, Elena Zamagni, 324346

PARATHYROID HORMONE LEVELS AND PROGNOSIS IN MULTIPLE MYELOMA?

EHA Library, Joanna Su Ling Tung, 324347

DEMOGRAPHIC, CLINICAL, AND PROGNOSTIC CHARACTERISTICS OF PRIMARY PLASMA CELL LEUKEMIA IN LATIN AMERICA, A STUDY OF GELAMM GROUP.

EHA Library, Macarena Roa, 324348

DEVELOPING A MULTI-MODULE E-HEALTH APPLICATION FOR PATIENTS WITH MULTIPLE MYELOMA RECEIVING COMPLICATED TREATMENT REGIMENS.

EHA Library, Paul Geerts, 324349

IMMUNOPHENOTYPIC PROFILE AND CLINICAL CHARACTERISTICS OF PRIMARY AND SECONDARY PLASMA CELL LEUKEMIA

EHA Library, Renata Bezdekova, 324350

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 324351

PREVALENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS.

EHA Library, Pablo Tenorio, 324352

RENAL IMPAIRMENT IN MULTIPLE MYELOMA: CHARACTERISTICS AND OUTCOMES OF 55 MOROCCAN PATIENTS

EHA Library, Mahtat EL MEHDI, 324353

FIRST-LINE TREATMENT OF OLDER PATIENTS WITH MULTIPLE MYELOMA (MM) WITH BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (VCD)

EHA Library, Konstantinos Liapis, 324354

SKELETAL RELATED EVENTS IN MULTIPLE MYELOMA: A RETROSPECTIVE SINGLE CENTRE ANALYSIS

EHA Library, Daniel Farrugia, 324355

FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF MEDITERRANEAN FEVER GENE MUTATIONS IN MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS

EHA Library, Isik Kaygusuz Atagunduz, 324356

DARATUMUMAB IN TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

EHA Library, Josip Batinić, 324357

LENALIDOMIDE VERSUS THALIDOMIDE OR BORTEZOMIB AS MAINTENANCE REGIMEN FOR NON-TRANSPLANT PATIENTS WITH MULTIPLE MYELOMA: MULTI-CENTER REAL WORLD EXPERIENCES IN CHINA

EHA Library, Junling Zhuang, 324358

CONVENTIONAL CYTOGENETIC ANALYSIS IN PATIENTS WITH MULTIPLE MYELOMA – SINGLE CENTER STUDY

EHA Library, Radi Lukanov, 324359

COMPARISON OF 140MG/M2 VS 200MG/M2 DOSE OF MELPHALAN IN MYELOMA AUTOGRAFT – A SINGLE CENTER EXPERIENCE FROM CHENNAI, INDIA.

EHA Library, Kishore Kumar, 324360

CLINICAL OUTCOMES OF IXAZOMIB-BASED REGIMENS IN CHINESE PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING BORTEZOMIB-BASED INDUCTION REGIMEN: PROTOCOL FOR MODIFY STUDY

EHA Library, Wenming Chen, 324361

CLINICAL CHARACTERISTICS AND OUTCOMES, OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA PATIENTS TREATED WITH ANTI-CD38 MONOCLONAL ANTIBODIES

EHA Library, Irene Zamanillo, 324362

THERAPEUTIC RESULTS OF BORTEZOMIB MULTIPLE MYELOMA TREATMENT: A MONOCENTRIC STUDY

EHA Library, Faten kallel, 324363

VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA (MM): UPDATED UKRAINIAN RETROSPECTIVE MULTICENTER ANALYSIS

EHA Library, Olga Novosad, 324364

THE HIGH-RISK CYTOGENETIC (HRC) INFLUENCES IN THE OUTCOME OF THE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM).

EHA Library, María Irene Nuevo López, 324365

REAL‐LIFE OUTCOMES OF DARATUMUMAB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: EXPERIENCE FROM A SMALL PERIPHERAL HOSPITAL

EHA Library, D. Rochate, 324366

REAL WORLD TWO-CENTER EXPERIENCE OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/ REFRACTORY MULTIPLE MYELOMA

EHA Library, IRENE SANCHEZ PRIETO, 324367

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 324368

FOUR PATIENTS DIAGNOSED OF AL AMYLOIDOSIS WITH SEVERE ORGAN DAMAGE WHO UNDERWENT AN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOLLOWING AN INDUCTION TREATMENT: EXPERIENCE IN A THIRD LEVEL HOSPITAL

EHA Library, Natalia Alba, 324369

REAL WORLD EVIDENCE OF CARFILZOMIB IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, VASILIKI DOUKA, 324370

DREAMM-5 PLATFORM TRIAL: BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH FIVE DIFFERENT NOVEL AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, PAUL RICHARDSON, 324371

A RAPID RESPONSE WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE COMBINATION IN A PATIENT WITH CASTLEMAN VARIANT OF POEMS SYNDROME

EHA Library, Yaşa Gül Mutlu, 324372

SCREENING OF SOMATIC MUTATIONS IN THE CALR GENE BY HIGH-RESOLUTION MELTING CURVE ANALYSIS

EHA Library, Dmitrij Kurochkin, 324373

SYSTEMIC MASTOCYTOSIS: A RETROSPECTIVE STUDY OF A SINGLE-CENTER’S EXPERIENCE ON A RARE DISEASE

EHA Library, Catarina Campos-Costa, 324374

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON JAK2 INHIBITOR THERAPY AND REQUIRING RBC TRANSFUSIONS (INDEPENDENCE TRIAL)

EHA Library, Ruben Mesa, 324375

THE FREQUENCY OF CD34+ CELLS PER CD45+ CELLS IN PERIPHERAL BLOOD ENUMERATED BY AUTOMATED METHOD IS EFFECTIVE AS A NON-INVASIVE MARKER OF MYELOFIBROSIS IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Takaaki Maekawa, 324376

CLINICAL BENEFIT IN REAL LIVE OF ALTERNATIVE RUXOLITINIB DOSING REGIME IN MYELOFIBROSIS PATIENTS

EHA Library, Francisca Hernandez Mohedo, 324377

REAL-LIFE RUXOLITINIB EXPERIENCE IN AN INTERMEDIATE-1 RISK PREDOMINANT COHORT

EHA Library, Tayfur Toptas, 324378

BIOEQUIVALENCE OF 50 MG ONCE-DAILY RUXOLITINIB EXTENDED RELEASE (XR) TABLETS COMPARED TO 25 MG TWICE-DAILY RUXOLITINIB IMMEDIATE RELEASE (IR) TABLETS

EHA Library, Xiaohua Gong, 324379

ESSENTIAL THROMBOCYTHEMIA AND THE RISK OF POLYPHARMACY: ASSESSMENT OF POTENTIAL DRUG-DRUG AND FOOD-DRUG INTERACTIONS

EHA Library, Mihnea-Alexandru Găman, 324380

LYMPHOPENIA IS HIGHLY PREVALENT IN OVERT MYELOFIBROSIS AT DIAGNOSIS AND ASSOCIATED WITH THE DEGREE OF ANEMIA AND THROMBOCYTOPENIA.

EHA Library, Tobias Silzle, 324381

SAFETY AND PHARMACOKINETICS OF BLU-263, A NEXT GENERATION KIT INHIBITOR, IN NORMAL HEALTHY VOLUNTEERS

EHA Library, Nimita Dave, 324382

GENERAL CHARACTERISTICS AND OUTCOME OF RENAL EXTRAMEDULLARY HEMATOPOIESIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS-A LITERATURE REVIEW

EHA Library, Shehab Mohamed, 324383

PACIFICA: A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS AND SEVERE THROMBOCYTOPENIA

EHA Library, John Mascarenhas, 324384

A PHASE 1 STUDY OF TP-3654, AN ORAL PIM KINASE INHIBITOR, IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS

EHA Library, Claudia Lebedinsky, 324385

A PHASE 1/2 STUDY OF INCB000928 AS MONOTHERAPY OR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS (INCB 00928-104)

EHA Library, Stephen Oh, 324386

A TWO-PART PHASE 2 STUDY OF ITACITINIB IMMEDIATE RELEASE IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WHO HAVE RECEIVED PRIOR RUXOLITINIB AND/OR FEDRATINIB MONOTHERAPY

EHA Library, Andrew Kuykendall, 324387

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ADD-ON PARSACLISIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE SUBOPTIMAL RESPONSE TO RUXOLITINIB

EHA Library, Abdulraheem Yacoub, 324388

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RUXOLITINIB PLUS PARSACLISIB IN PATIENTS WITH JAK- AND PI3K-INHIBITOR TREATMENT–NAÏVE MYELOFIBROSIS

EHA Library, Abdulraheem Yacoub, 324389

RELATIVE BIOAVAILABILITY AND DOSE LINEARITY OF FIVE STRENGTHS OF RUXOLITINIB EXTENDED RELEASE (XR) TABLETS

EHA Library, Xiaohua Gong, 324390

TUBERCULOSIS REACTIVATION FOLLOWING RUXOLITINIB THERAPY FOR MYELOFIBROSIS

EHA Library, Anil aribandi, 324391

A CASE OF POLYCYTHAEMIA VERA TREATED WITH ROPEGINTERFERON-2B DURING PREGNANCY

EHA Library, IRENE SANCHEZ PRIETO, 324392

A PHASE 1 STUDY OF INCB057643 MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (INCB 57643-103)

EHA Library, Justin M. Watts, 324393

CONSECUTIVE OCCURRENCE OF ACUTE MYELOID LEUKEMIA, CHRONIC LYMPHOCYTIC LEUKEMIA AND POLYCYTHEMIA VERA; EMERGENCE OF DRIVER MUTATIONS IN A CONTEXT OF CLONAL HEMOPOIESIS OF INDETERMINATE POTENTIAL.

EHA Library, VASILIKI DOUKA, 324394

ESSENTIAL THROMBOCYTEMIA IN THE YOUNG PATIENT: EXPERIENCE OF A SECONDARY HOSPITAL

EHA Library, Maria Remedios Arcas Vega, 324395

ADORE: A RANDOMIZED, OPEN-LABEL, PHASE 1/2 OPEN-PLATFORM STUDY EVALUATING SAFETY AND EFFICACY OF NOVEL RUXOLITINIB COMBINATIONS IN PATIENTS WITH MYELOFIBROSIS

EHA Library, David Ross, 324396

CLINICAL CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH PH NEGATIVE MYELOPROLIFERATIVE NEOPLASMS TREATED IN A REFERRAL HOSPITAL IN MEXICO CITY

EHA Library, Gilberto Barranco, 324397

SUCCESSFUL PREGNANCY OUTCOME IN ESSENTIAL THROMBOCYTAEMIA PATIENT AFTER MULTIPLE MISCARRIAGES WITH PLT NORMALISATION INDUCED BY GESTATIONAL THROMBOCYTOPENIA

EHA Library, Ines Vaide, 324398

MYELOFIBROSIS TREATMENT WITH RUXOLITINIB IN CLINICAL PRACTICE: AN ANALYSIS OF EFFICACY AND SAFETY OF A SINGLE CENTER

EHA Library, Rebeca Brito, 324399

RUXOLITINIB TREATMENT IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS (MPD) – A UNICENTER STUDY.

EHA Library, Vanessa Pereira, 324400

CHARACTERIZATION OF ADULTS SERIES OF MASTOCYTOSIS CASES IN A HEALTH CARE CENTER IN CALI

EHA Library, Jose Leonel Zambrano Urbano, 324401

OVERVIEW OF IMMUNE THROMBOCYTOPENIA MANAGEMENT IN CHILDREN, A SINGLE INSTITUTE EXPERIENCE

EHA Library, Hasanein Ghali, 324402

DENTOALVEOLAR PROCEDURES IN IMMUNE THROMBOCYTOPENIA; SYSTEMATIC REVIEW AND PRACTICAL RECOMMENDATIONS

EHA Library, Wobke E. M. van Dijk, 324403

CLINICAL AND BIOLOGICAL PREDICTORS OF CHRONICITY OF IMMUNE THROMBOCYTOPENIA IN ADULTS

EHA Library, Manel Bchir, 324404

NOT YET TO BE BORN – A CLINICAL CASE OF PSEUDOTHROMBOCYTOPENIA IN A PREGNANT WOMAN

EHA Library, Ana Catarina Marques, 324405

PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, ORAL BTK INHIBITOR, IN ADULTS AND ADOLESCENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA

EHA Library, David Kuter, 324406

REVISION OVER 15 YEARS EXPERIENCE OF MULTIPLE AUTOINMUNE CYTOPENIAS IN HEMATOLOGICAL AND NON-HEMATOLOGICAL DISORDERS

EHA Library, Paula Melero Valentín, 324407

HEALTH-RELATED QUALITY OF LIFE AMONG REFRACTORY/RELAPSED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH KTE-X19: PHASE 2 RESULTS FROM ZUMA-3 TRIAL

EHA Library, Caitlyn Solem, 324408

PSYCHOLOGICAL DISTRESS IN OUTPATIENTS WITH LYMPHOMA DURING THE COVID-19 PANDEMIC

EHA Library, Carla Minoia, 324409

REAL-WORLD COSTS OF FRONT-LINE TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA IN FRANCE, GERMANY, AND THE UNITED KINGDOM

EHA Library, Ajibade Ashaye, 324410

DETERMINING SATISFACTION WITH INTERPERSONAL RELATIONSHIP WITH NAVIGATOR MEASURE AMONG CAREGIVERS OF FILIPINO CHILDREN WITH CANCER IN A TERTIARY REFERRAL CENTER: A PATIENT NAVIGATION RESEARCH STUDY

EHA Library, Trixy Chu, 324411